OBIO vs XTNT vs NVCR vs BSX

For growth investors, Orchestra BioMed Holdings, Inc.

(OBIO) is the stronger pick with 1169% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Boston Scientific Corporation (BSX) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Orchestra BioMed Holdings, Inc. (OBIO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: BSX returned +155. 5% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Orchestra BioMed Holdings, Inc. 's 2. 21β — meaning OBIO is approximately 542% more volatile than BSX relative to the S&P 500. On balance sheet safety, Orchestra BioMed Holdings, Inc. (OBIO) carries a lower debt/equity ratio of 3% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Orchestra BioMed Holdings, Inc.

(OBIO) is pulling ahead at 1169% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, OBIO leads at 111. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -158. 2% for Orchestra BioMed Holdings, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -154. 7% for OBIO. At the gross margin level — before operating expenses — OBIO leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OBIO: 205.

3% to $12. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +155. 5% 10Y return). Orchestra BioMed Holdings, Inc. (OBIO) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BSX: +155. 5%, OBIO: -65. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OBIO is a small-cap high-growth stock; XTNT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; BSX is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.